Hosted on MSN3mon
AbbVie announces updated results from Phase 1b/2 EPCORE NHL-2 trialAbbVie (ABBV) announced updated results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered ...
AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgkin’s lymphoma.
Hosted on MSN1mon
People with aggressive form of blood cancer given fresh hope as two new drugs set to be rolled out by the NHSPeople with an aggressive form of blood cancer have been given fresh hope as two new drugs are set to be rolled out on the NHS. The medications, epcoritamab and loncastuximab tesirine, were ...
The drugmaker has reported top-line results from the phase 1/2 EPCORE trial of epcoritamab as a third-line therapy for relapsed/refractory LBCL, revealing an overall response rate of 63% and a ...
Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed/refractory DLBCL. The regimen also significantly extended survival. The addition of ...
Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of patients with relapsed or refractory or R/R, follicular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback